Entrada Therapeutics Inc (TRDA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.31 Million) by net assets ($340.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TRDA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Entrada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Entrada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entrada Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stack Capital Group Inc
TO:STCK
|
-0.013x |
|
Columbus Circle Capital Corp I Class A Ordinary Shares
NASDAQ:CCCM
|
-0.002x |
|
Tudor Gold Corp
V:TUD
|
-0.003x |
|
Huasi Agricultural Development Co Ltd
SHE:002494
|
-0.003x |
|
Imperial Brands PLC
LSE:IMB
|
-0.086x |
|
Taiwan Sanyo Electric Co Ltd
TW:1614
|
0.033x |
|
Pecca Group Bhd
KLSE:5271
|
0.122x |
|
Neumora Therapeutics, Inc.
NASDAQ:NMRA
|
-0.353x |
Annual Cash Flow Conversion Efficiency for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Entrada Therapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see TRDA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $428.68 Million | $-41.56 Million | -0.097x | -116.81% |
| 2023-12-31 | $242.36 Million | $139.80 Million | 0.577x | +230.73% |
| 2022-12-31 | $212.55 Million | $-93.79 Million | -0.441x | -159.14% |
| 2021-12-31 | $298.72 Million | $-50.86 Million | -0.170x | -127.63% |
| 2020-12-31 | $-41.49 Million | $-25.57 Million | 0.616x | -11.46% |
| 2019-12-31 | $-15.52 Million | $-10.80 Million | 0.696x | -- |
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more